Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07287189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Study acronym: BASECAMP
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fields
  2. Enrollment closed, study ongoing Study sites: 21 to 20 Show 1 more changeShow less
    • Study sites: 21 to 20
  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 21 of 21 sites Show 1 more changeShow less
    • Site details revised at 21 of 21 sites
  4. Eligibility criteria expanded, about 17 words Study description revised · Site details revised at 8 of 21 sites Show 2 more changesShow less
    • Study description revised
    • Site details revised at 8 of 21 sites
  5. Completion pushed from Jun 30, 2027 to Feb 28, 2028 Secondary endpoints: details revised at 3 of 4 entries · Study description expanded, about 57 wordsv21 Show 2 more changesShow less
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description expanded, about 57 words

    See this version in full on ClinicalTrials.gov ↗

Show 7 earlier versionsHide 7 earlier versions
  1. Site details revised at 2 of 21 sitesv20
  2. Site details revised at 1 of 21 sitesv19
  3. Site contacts updated at 1 of 21 sitesv18
  4. Site details revised at 2 of 21 sitesv17
  5. Site details revised at 1 of 21 sitesv16
  6. Site details revised at 1 of 21 sitesv15
  7. Site details revised at 1 of 21 sitesv14
  1. Trial sites reduced: 25 → 21 locationsv13
  2. Site details revised at 1 of 25 sitesv12
  3. Site details revised at 1 of 25 sitesv11
  4. Trial sites expanded: 19 → 25 locationsv10
  5. Study sites: 18 to 19v9
  6. Site contacts updated at 1 of 18 sitesv8
  7. Site details revised at 2 of 18 sitesv7
  8. Site details revised at 2 of 18 sitesv6
  9. Site contacts updated at 1 of 18 sitesv5
  10. Trial status: Active, Not Recruiting to Recruiting Site details revised at 18 of 18 sitesv4 Show 1 more changeShow less
    • Site details revised at 18 of 18 sites
  11. Primary completion date: Mar 31, 2026 to Mar 31, 2027 Completion date: Jun 30, 2026 to Jun 30, 2027v3 Show 1 more changeShow less
    • Completion date: Jun 30, 2026 to Jun 30, 2027
  12. Study title shortened, about 3 wordsv2 See this version in full on ClinicalTrials.gov ↗
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.
Trial Details
NCT Number NCT07287189
Lead Sponsor Satellos Bioscience, Inc.
Conditions Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Enrollment 51 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov